GU12-157
A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157
GU10-148
Phase II Trial of Gemcitabine, Cisplatin, Plus Ipilimumab as First-line Treatment for Patients With Metastatic Urothelial Carcinoma: Hoosier Cancer Research Network GU10-148
GU07-124
A Phase II Study of Neoadjuvant Dasatinib plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer
HCRN-BRE02-43
A Pilot Trial Incorporating ZD1839 (IRESSA®) into Adjuvant Therapy for Breast Cancer
GU10-147
Phase II Trial of Everolimus or Everolimus Plus Paclitaxel as First-line Therapy in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma: Hoosier Cancer Research Network GU10-147.
HCRN-BRE00-10
Phase I/II Trial of Chronic Low Dose Epirubicin and SU5416 in Patients with Previously Untreated Metastatic Breast Cancer
GU03-67
A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67
HCRN-LUN91-2
A Phase II Trial of CODE + G-CSF in Advanced NSCL
HCRN-GI00-11
A Phase II Study of Gemcitabine in Combination with Radiation Therapy in Patients with Localized Unresectable Pancreatic Cancer
GYN10-149
A Phase I-II Clinical Trial of Pegylated Liposomal Doxorubicin (Doxil®) in Combination With BIBF 1120 in Patients With Ovarian Cancer: Hoosier Oncology Group GYN10-149
HCRN-BRE99-1
Phase II Trial of Gemcitabine, Paclitaxel and Trastuzumab in Metastatic Breast Cancer: a Hoosier Oncology Group Trial
QL05-37
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
GU07-123
Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder
GU09-145
Phase I/II Study of BNC105P in Combination With Everolimus or Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma Following Prior Tyrosine Kinase Inhibitors
HCRN-GU96-1
A Phase II Trial of Doxil in the Treatment of Advanced Renal Cell Cancer
BRE98-1
Combined anti-microtubule therapy: A phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer, Hoosier Oncology Group BRE98-1
GU02-41
A Phase III, Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients with Metastatic Prostate Cancer Commencing Hormonal Therapy
HCRN-GYN06-111
A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis
GU07-122
A Pilot Study of Neoadjuvant Dasatinib Followed by Radical Cystectomy for Transitional Cell Carcinoma of the Bladder
LYM08-134
Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
HCRN-GI99-1
A Phase II Study of Gemcitabine and Docetaxel in Combination for Advanced Pancreatic Cancer
BTCRC-AML18-342
Phase I trial of azacitidine plus nivolumab following reduced-intensity allogeneic PBSC transplantation for patients with AML and high-risk myelodysplasia. Big Ten Cancer Research Consortium BTCRC-AML18-342
QL03-70
Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting
HCRN-LUN91-1
A Randomized Phase III Study of Definitive Radiation Therapy with or without Hydroxyurea in Previously Untreated Limited Unresectable Non-Small Cell Lung Cancer
HCRN-GU94-1
A Phase II Trial of Levamisole in the Treatment of Advanced Renal Cell Cancer
HCRN-HN96-1
A Phase II Trial of Doxil in Advanced or Recurrent Head and Neck Cancer
HCRN-QL02-45
Increasing Screening in Families with Colorectal Cancer
HCRN-QL02-44
Enhancing Connections: Helping the Mother with Breast Cancer Support Her Child
HCRN-GU91-1
A Phase II Study of Altretamine (HEX) for the Treatment of Metastatic Renal Cell Cancer
HCRN-GI98-1
Phase I/II Study of Gemcitabine and Docetaxel in Combination for Unresectable or Metastatic Pancreatic Cancer – GI98-1
GU04-75
A Phase II Trial of Cisplatin, Gemcitabine and Bevacizumab in Combination for Metastatic Transitional Cell Cancer: Hoosier Oncology Group GU04-75
LYM03-64
A Phase II Study of Rituximab and Gemcitabine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
HCRN-LUN90-1
Phase II Trial of Carboplatin plus Interferon Alpha-2a in Advanced Non-Small Cell Lung Cancer
HCRN-BRE96-1
Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer
GI06-112
A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer
HCRN-QL01-26
A Phase II Trial of Olanzapine (Zyprexa) for the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy
GU00-9
A Multicenter Randomized Phase II Study of Docetaxel plus Vinorelbine and Doxetacel plus Estramustine in Combination for Hormone Refractory Prostate Cancer
GI05-102
Phase I / Randomized Phase II Study of Second Line Therapy With Irinotecan and Cetuximab With or Without RAD001, an Oral mTOR Inhibitor for Patients With Metastatic Colorectal Cancer: Hoosier Oncology Group GI05-102
GYN06-106
A Phase 2, Open-Label, Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion Administered Orally in Patients With Recurrent or Resistant Epithelial Ovarian Cancer
HN02-40
A Single Arm Phase II Trial of Docetaxel and Capecitabine for the First Line Treatment of Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck
HCRN-QL01-22
Predictors of Quality of Life After Treatment for Colorectal Cancer
HCRN-LUN89-1
Phase II Study of VP-16 Plus Ifosfamide Plus Cisplatin (VIP) as Combination Chemotherapy for Previously Treated Small Cell Lung Cancer
GI05-92
A Pilot Study With Cetuximab and Radiation Therapy for Patients With Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group Study (GI05-92)
MDS04-85
A Phase II Randomized Trial with a Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients with Low-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts)
HCRN-GI91-1
Phase I/II Study of Weekly Oral MTX + AZT in the Treatment of Metastatic Adenocarcinoma of the Pancreas and Hepatoma – GI91-1
HCRN-MEL91-1
A Phase III Study Comparing Cisplatin, Dacarbazine, Carmustine and Tamoxifen vs Dacarbazine Alone in Patients with Advanced Melanoma
NHL01-27
Phase I/II Study of CHOP plus Ontak, an Interleukin-2 Fusion Toxin for Patients with Peripheral T-cell Non-Hodgkin’s Lymphomas
HCRN-HN94-1
A Phase II Trial of Ifosfamide in the Treatment of Advanced or Recurrent Squamous Cell Cancer of the Head and Neck
HCRN-GU90-1
Phase II Study of Recombinant Interferon Alpha-2a in Metastatic Renal Cell Cancer
MM08-141
A Phase I/II Trial of Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed or Refractory Multiple Myeloma: Hoosier Cancer Research Network MM08-141
